A significant prevalence of venous thromboembolism and CVD (cardiovascular disease) is the major factor in promoting the growth of the global heparin market. In 2018, the Centre for Disease Control and Prevention (CDC ) published a report in which it stated that more than 900,000 people only in the US are affected by deep vein thrombosis and pulmonary embolism every year. More than 18 million people die across the globe due to cardiovascular disorder this shows an immense opportunity for the heparin market to grow as heparin is the primary drug used as an anticoagulant used to prevent blood clotting.

A full report of Global Heparin Market is available at: https://www.omrglobal.com/industry-reports/heparin-market

Heart diseases such as CVD and stroke; among other heart diseases are the leading causes of mortalities across the globe. According to the CDC, every 40 seconds, an individual in the US has a heart attack. In addition, around 805,000 Americans have a heart attack every year. According to the WHO, around 17.9 million fatalities occur due to CVD in 2016, representing around 31% of global fatalities. Amongst these fatalities, around 7.4 million were due to CHD and approximately 6.7 million were due to stroke. By 2030, it has been projected that CVDs would be responsible for approximately 23.6 million mortalities across the globe. This growing prevalence of CVD induced the demand for the anticoagulant drug which will contribute to the heparin market.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/heparin-market

Various players are receiving FDA approval for their new heparin drug formulas which will contribute to the global heparin market in the near future. For instance, in April 2019, B. Braun Medical Inc. announced its launch of Heparin Sodium Injection, USP. It is an FDA approved and first of its kind syringe with attached needle for subcutaneous and intravenous use. It is designed with an aim to provide their patients with a better treatment experience with reduced risk of errors and expanding its product portfolio in the US in the medical field.

Global Heparin Market Segmentation

By Product

• Unfractionated Heparin
• Ultra-Low Molecular Weight Heparin (ULMWH)
• Low molecular weight Heparin (LMWH)

By Route of Administration

• Intravenous
• Subcutaneous

By Application

• Atrial Fibrillation & Heart Attack
• Coronary Heart Disease
• Pulmonary Embolism (PE)
• Deep Vein Thrombosis (DVT)
• Others

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/heparin-market

Global Heparin Market – Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• B Barun Melsungen AG
• Baxter International Inc.
• Eisai Co. Ltd.
• F. Hoffman-La Roche Ltd.
• Fresenius Kabi AG
• GlaxoSmithKline plc
• Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
• Hikma Pharmaceuticals PLC
• Leo Pharma A/S
• Mylan N.V.
• Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
• Novartis AG
• Opocrin S.P.A
• Pfizer Inc.
• Sanofi S.A.
• Syntex S.A.

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404